Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Tezepelumab (Primary) ; Immunotherapies
- Indications Hypersensitivity
- Focus Therapeutic Use
- 17 Mar 2017 Planned End Date changed from 1 Sep 2018 to 26 Feb 2019.
- 17 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 26 Feb 2019.
- 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.